Welcome to the Department of Radiation Oncology
Message from James M. Metz, MD — Chairman
Penn Radiation Oncology is dedicated to a three-part mission of excellence in patient care, basic and translational research, and the education of residents and students. We are committed to delivering excellence in every area and as such we steadfastly believe that "Excellence is Standard."
Penn Radiation Oncology is one of the most comprehensive radiation oncology programs in the world. The outstanding faculty and staff, combined with Penn’s extensive collection of advanced technology, gives patients access to nearly every treatment option available for their cancer. The broad range of radiation treatments available include proton therapy, intensity-modulated radiation therapy (IMRT), high-dose rate (HDR) and low-dose rate brachytherapy, partial breast irradiation, stereotactic radiosurgery (SRS), and Gamma Knife radiation. With the Abramson Cancer Center of the University of Pennsylvania, Penn Radiation Oncology provides patient care at the Ruth and Raymond Perelman Center for Advanced Medicine and seven community-based sites.
News
-
George Morcos, UPenn Biology Major, Awarded Thouron Scholarhip
Friday, March 8, 2024
Nine University of Pennsylvania affiliates—six fourth years and three recent graduates—have each received a 2024 Thouron Award to pursue graduate studies in the United Kingdom. Each Thouron Scholar receives tuition for up to two years, as well as travel and living stipends. George Morcos, from Rochester, New York, is majoring in biology with a concentration in molecular and cell biology, with minors in classical studies and nutrition in the College. As a University Scholar through the Center for Undergraduate Research & Fellowships, Morcos conducts research in the Koumenis Lab in Penn Medicine’s Department of Radiation Oncology. He is also a writing fellow at the Marks Family Center for Excellence in Writing and an advising fellow in the student club Matriculate, which provides mentorship to high school students. He is an undergraduate coordinator at the Heart Health Bridge to Care, an extension of the United Community Clinic of West Philadelphia focused primarily on management of hypertension, diabetes, and heart disease. Morcos is an American Association of Cancer Research Undergraduate Scholar and has presented his work at national conferences. As a Thouron Scholar, Morcos plans to pursue a master’s degree in pathology, conducting basic and translational research on therapeutic toxicities in cancer, at the University of Cambridge in England.
-
Dose-Escalated Radiation Therapy for High-Risk Localized Prostate Cancer
Friday, February 9, 2024
For patients with high-risk prostate cancer, treatment with long-term androgen deprivation therapy (ADT) and high-dose radiation was associated with significantly better survival compared with ADT and standard-dose radiation. Neha Vapiwala, MD, a professor of Radiation Oncology, who was not involved in the study, commented on the results during the 2024 American Society for Clinical Oncology Genitourinary Cancers Symposium.
-
Higher-Dose Radiation Therapy Extends Survival in High-Risk Prostate Cancer
Monday, January 29, 2024
For patients with high-risk prostate cancer, treatment with long-term androgen deprivation therapy (ADT) and high-dose radiation was associated with significantly better survival compared with ADT and standard-dose radiation. Neha Vapiwala, MD, a professor of Radiation Oncology, who was not involved in the study, commented on the results during the 2024 American Society for Clinical Oncology Genitourinary Cancers Symposium.